Androgenic deprivation therapy in prostate cancer is associated with the onset of different adverse effects, including osteoporosis and metabolic syndrome. Both are related to the onset of nephrolithiasis. The objective of this article is to study the incidence of renal stones in patients undergoing androgen deprivation therapy with LHRH analogue.
Case-control study including a total of 85 patients divided into 2 groups: group 1, with 41 patients on androgen deprivation therapy, and group 2, with 44 patients not receiving androgen deprivation therapy.
New-onset lithiasis was observed in 12 cases (29.3%) in group 1 compared to 2 cases (4.5%) in group 2 (P=.0001), 4.4 years after starting the androgen deprivation therapy. The estimated odds ratio was 8.69 (95% CI 1.81-41.76).
The incidence of renal stones could be increased in patients receiving treatment with analogue LHRH. However, long-term prospective studies with a metabolic control are required to be able to establish the causes explaining the development of this phenomenon in patients undergoing treatment with androgen deprivation therapy.
Medicina clinica. 2017 Feb 27 [Epub ahead of print]
Enrique Javier Díaz Convalía, María Del Carmen Cano-García, José Luis Miján-Ortiz, Miguel Arrabal-Martín, Miguel Ángel Arrabal-Polo, José Manuel Cózar-Olmo
Unidad de Gestión Clínica de Urología, Complejo Hospitalario Universitario de Granada, Granada, España., Unidad de Gestión Clínica de Urología, Complejo Hospitalario Universitario de Granada, Granada, España. Electronic address: .